Literature DB >> 2769647

Oestrogen induced suppression of collagen arthritis. IV: Progesterone alone does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect.

L Jansson1, R Holmdahl.   

Abstract

The effects of 17 beta-oestradiol and progesterone on the development of type II collagen-induced arthritis (CIA) and the anti-type II collagen (CII) autoantibody response were investigated. Treatment with physiological doses of 17 beta-oestradiol, inducing serum levels below the estradiol peak at the end of pregnancy, abrogated the development of arthritis and suppressed the anti-CII autoantibody response. Treatment with progesterone alone did not have significant effects on the development of arthritis or on the anti-CII autoantibody response. However, a combined treatment with both progesterone and oestrogen in physiological doses induced a more pronounced suppression of CIA than the suppression induced with oestrogen treatment alone. These findings suggest that oestrogen, but not progesterone, may be the critical factor to explain the pregnancy-related down-regulation of CIA.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2769647     DOI: 10.1016/0165-0378(89)90033-8

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  14 in total

1.  Agalactosyl IgG in pristane-induced arthritis. Pregnancy affects the incidence and severity of arthritis and the glycosylation status of IgG.

Authors:  S J Thompson; Y Hitsumoto; Y W Zhang; G A Rook; C J Elson
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

2.  Maintained pregnancy levels of oestrogen afford complete protection from post-partum exacerbation of collagen-induced arthritis.

Authors:  R Mattsson; A Mattsson; R Holmdahl; A Whyte; G A Rook
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

3.  Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis.

Authors:  C Jochems; U Islander; M Erlandsson; C Engdahl; M Lagerquist; C Ohlsson; K S Nandakumar; R Holmdahl; H Carlsten
Journal:  Clin Exp Immunol       Date:  2011-04-19       Impact factor: 4.330

Review 4.  Gender issues and multiple sclerosis.

Authors:  Rhonda R Voskuhl
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 5.081

5.  Pregnancy amelioration of arthritis in SKG mice corresponds with alterations in serum amyloid A3 levels.

Authors:  Laura A Shaw; Adrianne L Stefanski; Lisa K Peterson; Kristen K Rumer; Andrea Vondracek; Tzu L Phang; Shimon Sakaguchi; Virginia D Winn; Leonard L Dragone
Journal:  Am J Clin Exp Immunol       Date:  2012-04-20

6.  Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis.

Authors:  C Jochems; M Lagerquist; C Håkansson; C Ohlsson; H Carlsten
Journal:  Clin Exp Immunol       Date:  2008-04-24       Impact factor: 4.330

7.  Oestrogen-induced suppression of collagen arthritis; 17 beta-oestradiol is therapeutically active in normal and castrated F1 hybrid mice of both sexes.

Authors:  L Jansson; R Holmdahl
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

8.  Oestrogen is a potent disease accelerator in SLE-prone MRL lpr/lpr mice.

Authors:  H Carlsten; A Tarkowski; R Holmdahl; L A Nilsson
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

Review 9.  Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.

Authors:  Rhonda Voskuhl; Callene Momtazee
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

10.  Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis.

Authors:  Caroline Jochems; Ulrika Islander; Malin Erlandsson; Cecilia Engdahl; Marie Lagerquist; Inger Gjertsson; Claes Ohlsson; Rikard Holmdahl; Hans Carlsten
Journal:  BMC Musculoskelet Disord       Date:  2010-12-16       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.